|

Ruxolitinib Clinical Trials

34 actively recruiting trials across 15 locations

Also known as: (3R)-3-cyclopentyl-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile, 941678-49-5, INCB 018424, INCB-018424, INCB-18424 +6 more

Pipeline

Early 1: 1Phase 1: 10Phase 2: 17Phase 3: 1Phase 1/2: 5

Top Sponsors

  • Memorial Sloan Kettering Cancer Center3
  • M.D. Anderson Cancer Center3
  • University of Chicago2
  • St. Petersburg State Pavlov Medical University2
  • Jonathan Brammer2

Indications

  • Cancer33
  • Polycythemia Vera4
  • Myeloproliferative Neoplasms3
  • Essential Thrombocythemia3
  • Hypereosinophilic Syndrome2

Other7 trials

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Phase 1
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
Phase 2
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Phase 1/2
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
Phase 3
Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor
Phase 2
Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
Phase 2
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
Phase 2

Chicago, Illinois4 trials

Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation

University of Chicago Medicine Comprehensive Cancer Center

Phase 1
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

University of Illinois Cancer Center

Phase 1/2
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia

University of Chicago Medical Center

Phase 1
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Rush University

Phase 1/2

Miami, Florida3 trials

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

University of Miami (Data Collection Only)

Phase 1
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma

Miami Cancer Institute at Baptist Health, Inc.

Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

University of Miami

Phase 2

Columbus, Ohio3 trials

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 2
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1

Houston, Texas3 trials

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

M D Anderson Cancer Center

Early 1
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

MD Anderson Cancer Center

Phase 2
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)

The University of Texas M. D. Anderson Cancer Center

Phase 1/2

Duarte, California2 trials

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

City of Hope

Phase 1
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

City of Hope Medical Center

Phase 1

Boston, Massachusetts2 trials

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Dana-Farber Cancer Institute

Phase 2
Ruxolitinib in Thrombocythemia and Polycythemia Vera

Massachusetts General Hospital

Phase 2

Seattle, Washington2 trials

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Scottsdale, Arizona1 trial

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic in Arizona

Phase 1

La Jolla, California1 trial

Retifanlimab and Ruxolitinib In Solid Malignancies

University of California, San Diego Moores Cancer Center

Phase 1/2

Palo Alto, California1 trial

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

Stanford Cancer Institute Palo Alto

Phase 2

Stanford, California1 trial

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Stanford University

Phase 1

West Hollywood, California1 trial

A Trial of Selinexor, Ruxolitinib and Methylprednisolone

Berenson Cancer Center

Phase 1

Bethesda, Maryland1 trial

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

National Institutes of Health Clinical Center

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

New York, New York1 trial

Amping up With PemJAK

Columbia University Irving Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.